Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIDER: Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases
NCT05794971Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2023
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of irinotecan in colorectal cancer (CRC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Overall Survival at 24 months. Started Jun 2023; status: recruiting.
02
Drugs
irinotecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05794971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05794971.